Measurement of newly developed tumor markers and molecular markers in health screening for lung cancer

新开发的肿瘤标志物和分子标志物在肺癌健康筛查中的测定

• 批准号: 18590849
• 负责人: SHIMIZU Eiji
• 金额: $ 2.04万
• 依托单位: Tottori University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2006
• 资助国家: 日本
• 起止时间: 2006 至 2007
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-18590849/
• 关键词: lung cancer; serum; tumor marker; ProGRP; ULBP-2; anti-p53 autoantibody; コチニン

To establish serum markers for early diagnosis of lung cancer, we developed methods to detect a candidate for molecular marker. In addition, we conducted a large scale survey to confirm the performance of this marker in combination with known tumor markers, to detect lung cancer among healthy people. First, we developed Enzyme-Linked Immunosorbent Assay (ELISA) for detecting soluble ULBP-2. This ELISA system could detect elevated ULBP-2 in serum of lung cancer patients, but not in normal volunteers. These results indicated the usefulness of the ELISA systems. Secondly, to study the performance of the molecular and tumor markers in health screening for lung cancer, we recruited healthy volunteers in group health examination settings. We measured ProGRP, ULBP-2, anti-p53 autoantibody, and cotinine as a marker for small cell lung cancer, non-small cell lung cancer, lung cancer, and smoking habits, respectively. As a result, we revealed that these markers are independent indicators. Thirdly, we developed a new recruitment system to obtain complete personal information of the participants. We got 163 new participants using this system. Serum ProGRP was elevated in two (?20.0 pg/mL), but not exceed a normal level (46.0 pg/mL). Serum ULBP-2 was mildly (2 - 10 ng/ml), moderately (10 - 100 ng/ml), or highly (?100 ng/ml) elevated in five, three, or one subjects, respectively. We are planning to follow up this study population to find the onsets of lung cancer. In summary, supported by this grant, we made a sensitive method to detect a potential candidate of the molecular marker of lung cancer, verified the usefulness of it in combination with kwon tumor maker and autoantibody in cancer screening. In addition, we developed a new system of mass survey to confirm their performance in health screening settings. We believe this will lead to the development of new serum indicators for early detection of lung cancer.

为了建立肺癌早期诊断的血清标志物，我们开发了检测候选分子标志物的方法。此外，我们还进行了一项大规模的调查，以证实该标志物与已知的肿瘤标志物相结合，在健康人群中检测肺癌的性能。首先，我们建立了检测可溶性ULBP-2的酶联免疫吸附试验(ELISA)。该系统能检测到肺癌患者血清中ULBP-2的升高，但不能检测到正常人血清中ULBP-2的升高。这些结果表明所建立的酶联免疫吸附试验系统是有效的。其次，为了研究分子和肿瘤标志物在肺癌健康筛查中的作用，我们在团体健康检查环境中招募了健康志愿者。我们分别检测ProGRP、ULBP-2、抗P53自身抗体和可替宁作为小细胞肺癌、非小细胞肺癌、肺癌和吸烟习惯的标志物。因此，我们揭示了这些标记物是独立的指标。第三，我们开发了一个新的招聘系统，以获取参与者的完整个人信息。我们有163名新参与者使用这个系统。血清ProGRP有2例升高(20.0pg/m L)，但未超过正常水平(46.0pg/m L)。血清ULBP-2轻度升高(2~10 ng/ml)、中度升高(10~100 ng/ml)或高度升高(？100 ng/ml)分别为5例、3例和1例。我们正计划对这一研究人群进行追踪，以发现肺癌的发病情况。综上所述，在这笔资金的支持下，我们建立了一种敏感的方法来检测潜在的肺癌分子标志物，并验证了其与肿瘤标志物和自身抗体联合应用在癌症筛查中的有效性。此外，我们开发了一种新的大规模调查系统，以确认他们在健康筛查环境中的表现。我们相信，这将导致新的血清指标的发展，以早期发现肺癌。

项目成果

肺癌細胞株におけるセツキシマブを介した抗体依存的細胞傷害活性の検討(Antibody-Dependent Cellular Cytotoxicity Mediated by Cetuximab against Lung Cancer Cell Lines)

西妥昔单抗介导的针对肺癌细胞系的抗体依赖性细胞毒性

• 发表时间: 2007
• 作者: 倉井 淳;他
• 通讯作者: 他

Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer lines.

西妥昔单抗介导的针对肺癌细胞系的抗体依赖性细胞毒性。

• 发表时间: 2007
• 期刊: Clin Cancer Res 13(5)
• 作者: Kurai J;et al.
• 通讯作者: et al.

Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines

• DOI: 10.1158/1078-0432.ccr-06-1726
• 发表时间: 2007-03-01
• 期刊: CLINICAL CANCER RESEARCH
• 影响因子: 11.5
• 作者: Kurai, Jun;Chikumi, Hiroki;Shimizu, Eiji
• 通讯作者: Shimizu, Eiji

Dexamethasone inhibits paclitaxel-induced cytotoxic activity through retinoblastoma protein dephosphorylation in non-small cell lung cancer cells.

• DOI: 10.3892/ijo.30.1.187
• 发表时间: 2007
• 期刊: International journal of oncology
• 影响因子: 5.2
• 作者: M. Morita;H. Suyama;T. Igishi;Y. Shigeoka;M. Kodani;Kiyoshi Hashimoto;K. Takeda;T. Sumikawa;E. Shimizu

Dexamethasone interferes with trastuzumab-induced cell growth inhibition through restoration of AKT activity in BT-474 breast cancer cells.

• DOI: 10.3892/ijo.32.3.683
• 发表时间: 2008-03
• 期刊: International journal of oncology
• 影响因子: 5.2
• 作者: T. Sumikawa;Y. Shigeoka;T. Igishi;H. Suyama;A. Yamasaki;Kiyoshi Hashimoto;S. Matsumoto;K. Takeda;Y. Ueda;E. Shimizu